Genentech drug picked for pioneering $100M Alzheimer's trial
Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's.
TOP HEADLINES
Special Report
Top 10 Best-selling Cancer Drugs
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
Piramal bets on pharma's data binging in $635M buyout
The deal comes amid rapid business expansion at Decision Resources, which provides web-based research tools, predictive analytics and other services to drugmakers and other healthcare stakeholders.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
UPDATED: Upstart Ra sheds stealth status, targets new drug class
Two years after Ra snagged an initial $10 million in venture cash, the company has hauled in a second tranche of $8.6 million and picked its disease target: hereditary angioedema, a rare and lethal immune system disorder.
Achillion burnishes buyout prospects, snags fast track for hep C drug
Achillion CEO Michael Kishbauch hasn't been the least bit shy about touting the company's buyout prospects. Quick to boast about the biotech's promising hepatitis C drugs, he's been raising hopes and stirring buyout buzz with every appearance.
Elevation boasts 'gold standard' IIb data for COPD therapy
Today the biotech boasted that their therapy--EP-101--had registered positive data in a Phase IIb study, positioning it as a potential new "gold standard" in nebulized treatments for the ailment.
Latest Commentary
From Our Sister Sites
Knode has sprung to life with web-based software to enable life sciences stakeholders to hunt for top experts.
Sold on the growing need for data in biopharma, India's Piramal Healthcare has scooped up Decision Resources Group in deal valued at about $635 million.




POPULAR COMMENT THREADS